Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Hitler's madcap mega-railway would have linked Berlin with India - 2Pain at the pump for Hampton Roads residents
- 3Israeli girl suffers cardiac arrest during sirens in Safed, hospitalized in serious condition
- 4Slovakia rejects EU call to scrap higher fuel prices for foreign cars
- 5Visual communication Programming for Fledglings
- Rediscovering Experience Through Excursions: Individual Travel Stories
- Help Your Business with Master Web based Promoting Arrangements
- 4 well known subjects in school
- Former 'Bachelorette' welcomes 1st baby via emergency c-section
- The most effective method to Integrate Compact disc Rates into Your Retirement Arranging
- The Main 20 Photography Instagram Records to Follow
- Turning into a Sharp Financial backer: Individual budget Wins
- Zendaya serves bridal-coded fashion with old, new and borrowed gowns for ‘The Drama’ press tour
- 3D Printers for Specialists
